253 related articles for article (PubMed ID: 35716644)
1. Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder.
Frost MC; Richards JE; Blosnich JR; Hawkins EJ; Tsui JI; Edelman EJ; Williams EC
Drug Alcohol Depend; 2022 Aug; 237():109521. PubMed ID: 35716644
[TBL] [Abstract][Full Text] [Related]
2. Associations Between Distinct Co-occurring Substance Use Disorders and Receipt of Medications for Opioid Use Disorder in the Veterans Health Administration.
Frost MC; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
J Addict Med; 2023 May-Jun 01; 17(3):278-285. PubMed ID: 37267168
[TBL] [Abstract][Full Text] [Related]
3. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
Rogal S; Youk A; Agbalajobi O; Zhang H; Gellad W; Fine MJ; Belperio P; Morgan T; Good CB; Kraemer K
Am J Gastroenterol; 2021 Jul; 116(7):1406-1413. PubMed ID: 33811202
[TBL] [Abstract][Full Text] [Related]
4. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
5. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
7. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
8. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
[TBL] [Abstract][Full Text] [Related]
9. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
[TBL] [Abstract][Full Text] [Related]
10. Association of Early Opioid Withdrawal Treatment Strategy and Patient-Directed Discharge Among Hospitalized Patients with Opioid Use Disorder.
Alrawashdeh M; Rhee C; Klompas M; Larochelle MR; Poland RE; Guy JS; Kimmel SD
J Gen Intern Med; 2023 Aug; 38(10):2289-2297. PubMed ID: 36788169
[TBL] [Abstract][Full Text] [Related]
11. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
[TBL] [Abstract][Full Text] [Related]
12. Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
Xu KY; Jones HE; Schiff DM; Martin CE; Kelly JC; Carter EB; Bierut LJ; Grucza RA
Obstet Gynecol; 2023 Apr; 141(4):845-853. PubMed ID: 36897142
[TBL] [Abstract][Full Text] [Related]
13. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
Mauro PM; Gutkind S; Annunziato EM; Samples H
JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
[TBL] [Abstract][Full Text] [Related]
14. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
15. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
[No Abstract] [Full Text] [Related]
16. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
17. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
[TBL] [Abstract][Full Text] [Related]
18. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
[TBL] [Abstract][Full Text] [Related]
20. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".
Krawczyk N; Rivera BD; Jent V; Keyes KM; Jones CM; Cerdá M
Int J Drug Policy; 2022 Dec; 110():103786. PubMed ID: 35934583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]